Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Clinical trial NCT03661723 · COMPLETED
Trial details
- NCT number
- NCT03661723
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-28
- Primary completion
- 2021-12-09
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.